Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TARGET Study: Individualized fludarabine dosing during innate allogeneic stem cell transplantation
2018-000356-18Phase 2Completed
- Sponsor
- University Medical Center Utrecht
- Start
- Jul 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of fludarabine in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), acute lymphoblastic leukemia (ALL) and 5 more (2 arms), sponsored by University Medical Center Utrecht. Primary endpoint: Cumulative incidence of severe viral infections (> grade 2) until day 100. Started Jul 2018; status: completed.
02
Drugs
fludarabine
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)acute lymphoblastic leukemia (ALL)chronic myelogenous leukemia (CML)chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2018-000356-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000356-18.